These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1706239)

  • 1. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.
    Boyer V; Broly H; Souche S; Madaule P; Rossier J; Zagury D; Desgranges C
    Clin Exp Immunol; 1991 Mar; 83(3):452-9. PubMed ID: 1706239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.
    Nakamura GR; Byrn R; Rosenthal K; Porter JP; Hobbs MR; Riddle L; Eastman DJ; Dowbenko D; Gregory T; Fendly BM
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1875-85. PubMed ID: 1283308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.
    Ohlin M; Broliden PA; Danielsson L; Wahren B; Rosen J; Jondal M; Borrebaeck CA
    Immunology; 1989 Nov; 68(3):325-31. PubMed ID: 2480328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.
    Liou RS; Rosen EM; Fung MS; Sun WN; Sun C; Gordon W; Chang NT; Chang TW
    J Immunol; 1989 Dec; 143(12):3967-75. PubMed ID: 2480382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
    Akerblom L; Hinkula J; Broliden PA; Mäkitalo B; Fridberger T; Rosen J; Villacres-Eriksson M; Morein B; Wahren B
    AIDS; 1990 Oct; 4(10):953-60. PubMed ID: 1702001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.
    Robert V; Resnicoff M; Chermann JC; Devaux C
    Mol Cell Biochem; 1991 Apr; 102(2):115-23. PubMed ID: 1715507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I.
    Teeuwsen VJ; Siebelink KH; Crush-Stanton S; Swerdlow B; Schalken JJ; Goudsmit J; van de Akker R; Stukart MJ; Uytdehaag FG; Osterhaus AD
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):381-92. PubMed ID: 1692724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop.
    Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
    Akerblom L; Nara P; Dunlop N; Morein B
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects.
    Wong MT; Warren RQ; Anderson SA; Dolan MJ; Hendrix CW; Blatt SP; Melcher GP; Boswell RN; Kennedy RC
    J Infect Dis; 1993 Dec; 168(6):1523-7. PubMed ID: 7504036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.